Grants Awarded

Principal Investigator Title and (Awardee*) Grant Period Total amount of Award
(Direct Costs)
Source of Funding

Neel Krishna (PI)
Kenji Cunnion (Co-I)

PIC1 pre-clinical formulation and optimization as a novel anti-inflammatory pharmacological agent

6/06/2019 – 5/31/2021

$1,498,000

NIH SBIR Phase II
NIAID

Tushar Shah (PI)
Neel Krishna (Co-I)

Development of Peptide Inhibitor of Complement C1 as a treatment for neonatal hypoxic-ischemic encephalopathy

10/1/2017 – 3/31/2019

$400,000

VA Catalyst

Neel Krishna (PI)
Kenji Cunnion (Co-I)

Optimization of PIC1 treatment in a rat model of transfusion related acute lung injury (TRALI)

4/01/2018 – 3/31/2020

$300,000

Commonwealth Transfusion Foundation

Kenji Cunnion (PI)
Neel Krishna (Co-I)

Peptide inhibitors of oxidative heme toxicity in acute hemolysis

8/01/2018 – 7/31/2020

$275,000

NIH/NHLBI

Kenji Cunnion (PI)
Neel Krishna (Co-I)

PIC1 inhibition of myeloperoxidase activity

5/03/2018 – 4/30/2020

$275,000

NIH/NIAID

Kenji Cunnion (PI)
Neel Krishna (Co-I)

PIC1 treatment for platelet refractoriness

8/01/2017 – 7/31/2019

$249,000

Commonwealth Transfusion Foundation

Neel Krishna (PI)
Kenji Cunnion (Co-I)

Peptide Inhibitor of Complement C1 (PIC1) as a treatment for autoimmune hemolytic anemia in patients with systemic lupus erythematosus

6/17/2019 – 6/16/2020

$50,000

CRCF/CIT

Kenji Cunnion (PI)
Neel Krishna (Co-I)

PIC1 inhibition of myeloperoxidase activity

10/01/2017 – 9/30/2019

$50,000

Cystic Fibrosis Foundation

Tushar Shah (PI)
Kenji Cunnion (Co-I)

Development of PIC1 to treat neonatal asphyxia brain damage

6/20/2017 – 5/31/2018

$271,000

NIH/NIAID
SBIR Phase I

Kenji Cunnion (PI)
Neel Krishna (PI, EVMS subaward)

Peptide inhibitors of antibody-initiated complement activation that block auto-immune damage

04/2016 – 10/2016

$150,000

NIH/NIAID
SBIR Phase I

12 Additional Awards involving PIC1 in various indications

2009 – 2016

$885,000

Multiple Federal, state and private agencies

Total Awards

$4,403,000

* Prior to ReAlta Life Sciences (RLS) company formation in January 2018, PIC1-related awards were made to Eastern Virginia Medical School (EVMS).

Loading...